CooperVision has completed enrollment of its global MiSight® 1 day* post-approval clinical studies (PAS) in the U.S. and China, a milestone in real-world evidence generation for pediatric myopia control. Together, these studies represent the longest1-3 international clinical evidence program ever undertaken for soft contact lens-based myopia control intervention in children, including both randomized controlled efficacy trials and large-scale safety registries.1,4-8
The combined PAS programs span more than 100 clinical sites and include over 3,000 children.9 Data will supplement already extensive MiSight® 1 day international clinical studies, which have been widely published and cited in the ophthalmology and optometry communities.1,4-8 Participants in the multi-year studies represent populations across the U.S. and China, providing insights applicable to children worldwide. Final data is expected on a rolling basis between 2027 and 2030.
“As clinicians, we all want long-term, real-world data that mirrors how myopia control is actually practiced,” said Jennifer Palombi, OD, FAAO, Director, Professional Affairs, Americas, CooperVision. “Completing enrollment in these post-approval studies is an important step forward for our category. MiSight® 1 day was built on a strong foundation of clinical evidence, and this next phase will add meaningful insights that can help Eye Care Professionals (ECPs) feel even more confident when managing pediatric myopia and guiding families through long-term care decisions.”1,4-8
The announcement coincides with 2026 Myopia Awareness Week (May 18 – 24), reinforcing the company’s ongoing commitment to advancing the science and understanding of pediatric myopia, a condition expected to affect nearly half of the global population by 2050.10
Building on this latest milestone, CooperVision has also released Progress in Focus: The Global Impact of MiSight® 1 day. The report brings together the far-reaching body of evidence and highlights the evolution of the MiSight® 1 day product. The resource reflects CooperVision’s broader commitment to advancing myopia management through ongoing research and innovation, while supporting ECPs in their conversations with patients, parents, and colleagues. To learn more about CooperVision’s myopia management research journey, read Progress in Focus at https://online.flippingbook.com/view/645323420/ or visit www.coopervision.com.
